Trial Type: Non-Hodgkin Lymphoma

S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Protocol Status: OPEN TO ACCRUAL
Contact: Olszewski, Adam
BRUOG-401-ADD
BrUOG 401: A Phase 2 Study of Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Protocol Status: OPEN TO ACCRUAL
Contact: Olszewski, Adam
A052101
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma
Protocol Status: OPEN TO ACCRUAL
Contact: Olszewski, Adam
BH-P-GOLSEEK-4
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator’s Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy
Protocol Status: OPEN TO ACCRUAL
Contact: Olszewski, Adam
BH-P-PORTAL
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
Protocol Status: OPEN TO ACCRUAL
Contact: Ollila, Thomas
LS-P-LOTIS-7
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Protocol Status: OPEN TO ACCRUAL
Contact: Pelcovits, Ari